Giulia Ferrannini

TL;DR: This exploratory analysis suggests that the cardioprotective effect of dulaglutide does not depend on baseline metformin therapy, and supports the recommendation of using agents with proven cardioprotsective efficacy without metformIn in patients with diabetes and additional cardiac risk factors.

TL;DR: In this article, the authors used liquid chromatography/tandem mass spectrometry to measure mannose concentrations in a discovery cohort and a validation cohort of carefully phenotyped individuals.

TL;DR: In a CCTA-based cohort, four proteins, involved in opposing vascular processes (healing vs. adverse remodeling), are specifically associated with low CAD burden in high CV-risk individuals and high CADurden in low-risk subjects (high PS-3 and PAF-AH), in interaction with BMI, smoking, diabetes, HDL-cholesterol, and HbA1c.

TL;DR: Type 2 diabetes in patients with coronavirus disease-19 (COVID-19) is associated with worse prognosis because of the use of sodium-glucose cotransporter 2 inhibitors, and SGLT2i and DPP-4i use was associated with higher risk of incident severe CO VID-19.

TL;DR: Sodium-glucose cotransporter 2 inhibitors were first discovered as glucose-lowering drugs because of their glycosuric action and good safety profile as discussed by the authors , which paved the way to a larger use of these drugs in patients with heart failure, with the aim of improving their clinical outcomes and quality of life.